#Pharmaceuticals #Investment #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ("Crinetics"), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, $350.
#Healthcare #PharmacyServices #CommunityHealth
www.beckershospitalreview.com
New Research Shows Increased Urgency to Improve Community Pharmacy Access and Reduce Gaps in Service
VytlOne Releases 2nd Annual Healthcare Leader Report -- Reviving Access, Reclaiming Revenue: Strengthening Hospitals and Communities Through Strategic Pharmacy Expansion
AMARILLO, Texas, Nov.
#DepressionTreatment #FDAApproval #Pharmaceuticals
www.benzinga.com
Why Is GH Research Stock Soaring Monday? - GH Research (NASDAQ:GHRS)
The U. S. Food and Drug Administration (FDA) on Monday lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) for GH001.
#WeightManagement #ObesityTreatment #PharmaceuticalInnovation
www.nasdaq.com
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
Last month, Novo Nordisk NVO announced the FDA approval of the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the long term, and to reduce the risk of major adverse cardiovascular (CV) events.
#Pharmaceuticals #Oncology #HealthcareConference
www.benzinga.com
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Corbus Pharmaceuticals (NASDAQ:CRBP)
NORWOOD, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.
#Pharmaceuticals #ClinicalTrials #DrugDevelopment
www.nasdaq.com
Crinetics To Provide Update On PALSONIFY And Topline Results From Phase 2 Trial Of Atumelnant In CAH
(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) is scheduled to host a conference call to provide an update on its lead drug PALSONIFY's commercialisation and disclose topline results from the fourth cohort of its Phase 2 trial of Atumelnant in congenital adrenal hyperplasia or CAH, today.
S
#Pharmaceuticals #Healthcare #MultipleSclerosis
www.streetinsider.com
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.
#Pharmaceuticals #MultipleSclerosis #FDAApproval
www.barchart.com
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
TAINAN , Jan.
#Hypertension #HeartHealth #Pharmaceuticals
www.benzinga.com
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterIdorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.
#AI #Oncology #Pharmaceuticals
www.benzinga.com
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterInsilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.
S
#Pharmaceuticals #EndocrineDiseases #ClinicalTrials
www.streetinsider.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.
#Pharmaceuticals #ClinicalTrials #EndocrineDiseases
www.benzinga.com
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia - Crinetics Pharmaceuticals (NASDAQ:CRNX)
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
#Biotech #Obesity #Pharmaceuticals
www.forbes.com
How A Wall Street Analyst Started A $4 Billion Obesity Drug Company
Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it's now a prime M&A target for giants jostling for their share of a potential $100 billion market.
#Healthcare #Pharmaceuticals #MarkCuban
www.benzinga.com
Why Was It Mark Cuban Who Took On Big Pharma? 'I'm Rich As F*** And I Didn't Care About The Money'
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Mark Cuban said that the reason he took on big pharma with his online pharmacy Cost Plus Drugs was that he could.
